Anshu Arundhati, Tan Donald, Chee Soon-Phaik, Mehta Jod S, Htoon Hla M
Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore, Singapore, 168751.
Cochrane Database Syst Rev. 2017 Aug 24;8(8):CD011908. doi: 10.1002/14651858.CD011908.pub2.
Cytomegalovirus (CMV) is a virus that usually affects people with reduced immunity. In recent years, this virus has been thought to cause repeated inflammation in the eye, in otherwise healthy people. This form of inflammation can cause damage to the cornea (the outer layer of the eye) or to the optic nerve by causing secondary glaucoma, or to both, leading to visual loss.
Our primary objective was to assess the effects of drug therapies for the treatment of CMV-associated anterior segment inflammation.Our secondary objective was to determine the optimal dose and duration of treatment with respect to recurrence and adverse effects.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2017, Issue 2), MEDLINE Ovid (1946 to 21 March 2017), Embase Ovid (1947 to 21 March 2017), the ISRCTN registry (www.isrctn.com/editAdvancedSearch); searched 21 March 2017, ClinicalTrials.gov (www.clinicaltrials.gov); searched 21 March 2017, and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en); searched 21 March 2017. We did not use any date or language restrictions in the electronic searches for trials. Two review authors independently reviewed the titles and abstracts.
We searched for randomised controlled trials (RCTs) on the management of CMV-associated anterior segment inflammation.
We planned to have two review authors independently extract data from reports of included studies and analyse data based on methods expected by Cochrane.
We did not identify any RCTs that met our inclusion criteria.
AUTHORS' CONCLUSIONS: There is currently no good-quality evidence on the management of CMV-associated anterior segment inflammation. Ideally, a well-designed RCT is needed to evaluate the effectiveness of different anti-CMV medications as well as the optimal dose and duration.
巨细胞病毒（CMV）是一种通常感染免疫力低下人群的病毒。近年来，人们认为这种病毒会在原本健康的人群中引发眼部反复炎症。这种炎症形式可通过引发继发性青光眼对角膜（眼球外层）或视神经造成损害，或同时对两者造成损害，导致视力丧失。
我们的主要目的是评估药物治疗巨细胞病毒相关性眼前节炎症的效果。我们的次要目的是确定关于复发和不良反应方面的最佳治疗剂量和疗程。
我们检索了考克兰对照试验中心注册库（CENTRAL）（其中包含考克兰眼科和视力试验注册库）（2017年第2期）、MEDLINE Ovid（1946年至2017年3月21日）、Embase Ovid（1947年至2017年3月21日）、国际标准随机对照试验编号注册库（www.isrctn.com/editAdvancedSearch）；于2017年3月21日进行检索，检索了美国国立医学图书馆临床试验注册库（ClinicalTrials.gov）（www.clinicaltrials.gov）；于2017年3月21日进行检索，以及世界卫生组织国际临床试验注册平台（ICTRP）（www.who.int/ictrp/search/en）；于2017年3月21日进行检索。我们在电子检索试验时未使用任何日期或语言限制。两名综述作者独立审阅了标题和摘要。
我们检索了关于巨细胞病毒相关性眼前节炎症管理的随机对照试验（RCT）。
我们计划让两名综述作者独立从纳入研究的报告中提取数据，并根据考克兰预期的方法进行数据分析。
我们未识别出任何符合我们纳入标准的随机对照试验。
目前尚无关于巨细胞病毒相关性眼前节炎症管理的高质量证据。理想情况下，需要进行一项设计良好的随机对照试验来评估不同抗巨细胞病毒药物的有效性以及最佳剂量和疗程。
